Payment overview · 2025
General Payments
$723.98
39 reported records · 8 companies
Healthcare provider profile · identity verified
Diane M Cozzo
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · BUFFALO, NY · NPI 1215019930
Verified facts
What the public records show
CMS Open Payments records show Diane M Cozzo received $723.98 in general payments during 2025 across 39 reported records.
Novo Nordisk Inc accounted for 21.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Mounjaro, Ozempic, Rybelsus.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 131 claims for Jardiance by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNJARDY as an associated drug or biological on 33 records involving 33 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Synjardy by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 181 claims for Eliquis by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 131 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 181 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $158.17 | 21.9% | 7 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $145.78 | 20.1% | 12 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $122.15 | 16.9% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $119.63 | 16.5% | 7 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $87.94 | 12.2% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $55.10 | 7.6% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $21.23 | 2.9% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $13.98 | 1.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $723.98 | 39 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $122.15 | 4 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $119.63 | 7 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $107.06 | 10 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $102.65 | 6 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $87.94 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $87.94 | 4 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $83.88 | 9 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $60.63 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $60.63 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $38.72 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $38.72 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $38.72 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $37.71 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $23.18 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $21.23 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $17.39 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $16.17 | 1 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $13.98 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 181 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 131 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 49 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 57 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
131 | 31 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | SYNJARDY open payments reported associated product |
CMS Open Payments — General Payments 33 supporting records · 33 recipient NPIs · example record 1222725005 |
Synjardy · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
181 | 40 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
131 | 31 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
49 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
57 | 13 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
181 | 40 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
20 | 20 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 438 | 127 |
| Atorvastatin Calcium | Atorvastatin Calcium | 416 | 120 |
| Levothyroxine Sodium | Levothyroxine Sodium | 341 | 90 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 289 | 90 |
| Pantoprazole Sodium | Pantoprazole Sodium | 288 | 71 |
| Metoprolol Succinate | Metoprolol Succinate | 272 | 81 |
| Gabapentin | Gabapentin | 259 | 53 |
| Omeprazole | Omeprazole | 246 | 62 |
| Lisinopril | Lisinopril | 238 | 73 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 218 | 52 |
| Eliquis | Apixaban | 181 | 40 |
| Escitalopram Oxalate | Escitalopram Oxalate | 172 | 37 |
| Trazodone Hcl | Trazodone Hcl | 168 | 33 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 160 | 44 |
| Allopurinol | Allopurinol | 158 | 47 |
| Famotidine | Famotidine | 131 | 39 |
| Jardiance | Empagliflozin | 131 | 31 |
| Spironolactone | Spironolactone | 131 | 32 |
| Synthroid | Levothyroxine Sodium | 129 | 34 |
| Furosemide | Furosemide | 125 | 36 |
| Metoprolol Tartrate | Metoprolol Tartrate | 124 | 24 |
| Hydrochlorothiazide | Hydrochlorothiazide | 122 | 37 |
| Clopidogrel | Clopidogrel Bisulfate | 112 | 29 |
| Ezetimibe | Ezetimibe | 111 | 33 |
| Simvastatin | Simvastatin | 109 | 32 |
| Metformin Hcl | Metformin Hcl | 106 | 38 |
| Losartan Potassium | Losartan Potassium | 104 | 29 |
| Tamsulosin Hcl | Tamsulosin Hcl | 104 | 32 |
| Duloxetine Hcl | Duloxetine Hcl | 102 | 25 |
| Bupropion Xl | Bupropion Hcl | 101 | 21 |
| Celecoxib | Celecoxib | 98 | 23 |
| Potassium Chloride | Potassium Chloride | 94 | 22 |
| Ibuprofen | Ibuprofen | 93 | 19 |
| Fluticasone Propionate | Fluticasone Propionate | 90 | 39 |
| Carvedilol | Carvedilol | 87 | 26 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 85 | 21 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 84 | 40 |
| Atenolol | Atenolol | 82 | 22 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 81 | 21 |
| Quetiapine Fumarate | Quetiapine Fumarate | 80 | 14 |
| Sertraline Hcl | Sertraline Hcl | 76 | 20 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 72 | 17 |
| Clonidine Hcl | Clonidine Hcl | 71 | 23 |
| Xarelto | Rivaroxaban | 71 | 12 |
| Prednisone | Prednisone | 70 | 37 |
| Azithromycin | Azithromycin | 69 | 62 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 68 | 12 |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 67 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 65 | 31 |
| Azelastine Hcl | Azelastine Hcl | 64 | 31 |
| Metformin Hcl Er | Metformin Hcl | 64 | 20 |
| Mirtazapine | Mirtazapine | 62 | 13 |
| Glimepiride | Glimepiride | 61 | 19 |
| Citalopram Hbr | Citalopram Hydrobromide | 58 | 11 |
| Ozempic | Semaglutide | 57 | 13 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 56 | suppressed |
| Topiramate | Topiramate | 56 | 12 |
| Doxepin Hcl | Doxepin Hcl | 53 | 12 |
| Irbesartan | Irbesartan | 53 | 15 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 53 | 19 |
| Meloxicam | Meloxicam | 53 | 17 |
| Alprazolam | Alprazolam | 51 | 26 |
| Buspirone Hcl | Buspirone Hcl | 50 | 13 |
| Bumetanide | Bumetanide | 49 | 16 |
| Montelukast Sodium | Montelukast Sodium | 49 | suppressed |
| Mounjaro | Tirzepatide | 49 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 49 | 12 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 47 | 12 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 46 | 14 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 46 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 45 | suppressed |
| Valsartan | Valsartan | 45 | 13 |
| Pravastatin Sodium | Pravastatin Sodium | 44 | 14 |
| Methylprednisolone | Methylprednisolone | 43 | 40 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 42 | 11 |
| Baclofen | Baclofen | 35 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 34 | suppressed |
| Lovastatin | Lovastatin | 34 | 12 |
| Valacyclovir | Valacyclovir Hcl | 34 | 15 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 32 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 31 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 31 | 12 |
| Pregabalin | Pregabalin | 31 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 31 | 11 |
| Cephalexin | Cephalexin | 29 | 26 |
| Febuxostat | Febuxostat | 28 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 27 | 23 |
| Liothyronine Sodium | Liothyronine Sodium | 27 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 27 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 27 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 26 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 26 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 26 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 24 | 15 |
| Trulicity | Dulaglutide | 24 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 24 | suppressed |
| Nifedipine Er | Nifedipine | 23 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 23 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 22 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 22 | suppressed |
| Rybelsus | Semaglutide | 22 | suppressed |
| Acyclovir | Acyclovir | 21 | suppressed |
| Clonazepam | Clonazepam | 21 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 21 | suppressed |
| Diazepam | Diazepam | 21 | 11 |
| Nortriptyline Hcl | Nortriptyline Hcl | 21 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 21 | suppressed |
| Aripiprazole | Aripiprazole | 20 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 20 | 18 |
| Lorazepam | Lorazepam | 20 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 20 | 20 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 20 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 20 | suppressed |
| Sucralfate | Sucralfate | 20 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 19 | suppressed |
| Chlorthalidone | Chlorthalidone | 19 | suppressed |
| Folic Acid | Folic Acid | 19 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 19 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 18 | 18 |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 18 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 17 | suppressed |
| Xifaxan | Rifaximin | 17 | suppressed |
| Colchicine | Colchicine | 16 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 16 | suppressed |
| Methocarbamol | Methocarbamol | 16 | suppressed |
| Amoxicillin | Amoxicillin | 15 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 15 | suppressed |
| Finasteride | Finasteride | 15 | suppressed |
| Ketoconazole | Ketoconazole | 15 | suppressed |
| Lansoprazole | Lansoprazole | 15 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 15 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 15 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 15 | suppressed |
| Ramipril | Ramipril | 15 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 15 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 15 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 14 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 14 | suppressed |
| Brilinta | Ticagrelor | 13 | suppressed |
| Creon | Lipase/Protease/Amylase | 13 | suppressed |
| Linzess | Linaclotide | 13 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 13 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Desloratadine | Desloratadine | 12 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 12 | suppressed |
| Indomethacin | Indomethacin | 12 | suppressed |
| Lactulose | Lactulose | 12 | suppressed |
| Metronidazole | Metronidazole | 12 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 12 | suppressed |
| Nadolol | Nadolol | 12 | suppressed |
| Probenecid-Colchicine | Probenecid/Colchicine | 12 | suppressed |
| Propylthiouracil | Propylthiouracil | 12 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 11 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 11 | suppressed |
| Entresto | Sacubitril/Valsartan | 11 | suppressed |
| Fluconazole | Fluconazole | 11 | suppressed |
| Glipizide | Glipizide | 11 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 11 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Lotrel | Amlodipine Besylate/Benazepril | 11 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 11 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 11 | suppressed |
| Repatha Syringe | Evolocumab | 11 | suppressed |
| Tadalafil | Tadalafil | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $723.98 · 39 records | Novo Nordisk Inc | ABRYSVO, AIRSUPRA, CAMZYOS, COMIRNATY, ELIQUIS, FARXIGA, JARDIANCE, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, PREVNAR 20, REPATHA, Rybelsus, VOQUEZNA, Wegovy, ZAVZPRET, ZEPBOUND | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error